Danaher Q1 EPS Tops Estimates While Sales Rise 3.5%, PT Hits $245
Danaher reported Q1 adjusted EPS of $2.06, a 9.6% increase year-over-year, beating estimates by $0.11 while sales rose 3.5% to $5.95 billion, narrowly missing forecasts. The company’s Life Sciences segment drove growth and management raised its 2026 earnings outlook and Jefferies lifted its price target to $245, a 26% upside.
1. Q1 Financial Results
Danaher delivered adjusted EPS of $2.06, up 9.6% year-over-year and $0.11 above consensus, while revenue grew 3.5% to $5.95 billion, slightly below expectations of $5.99 billion.
2. Segment Performance
The Life Sciences segment saw revenue rise 3.5% to $1.74 billion, driving overall growth, whereas Diagnostics experienced a decline, underscoring the need for portfolio enhancement.
3. Strategic Acquisition
Danaher announced plans to acquire Masimo to strengthen its Diagnostics offerings and expand its product portfolio in high-growth healthcare markets.
4. Outlook and Analyst Reaction
Management raised the 2026 earnings outlook based on segment momentum, and Jefferies increased its price target to $245, implying a 26% upside from recent levels.